WEST CHESTER, PA — Molecular Targeting Technologies Inc. reported updated clinical data from 81 patients with gastroenteropancreatic neuroendocrine tumors treated with its experimental radiopharmaceutical EBTATE, results that the company says support continued development of the therapy and its broader albumin-binding drug platform.
The West Chester-based clinical-stage radiopharmaceutical developer presented the findings at the 2026 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, highlighting what it described as one of the largest clinical datasets reported for an albumin-binding peptide receptor radionuclide therapy, or PRRT.
According to the company, patients treated with ¹⁷⁷Lu-DOTA-EB-TATE achieved a 50% objective response rate, a 100% disease control rate, and a median progression-free survival of 36 months.
Molecular Targeting Technologies reported approximately eight times greater tumor uptake than conventional PRRT approaches and said no kidney toxicity had been observed through one year of follow-up. The company also reported equivalent renal absorbed doses regardless of whether amino acid infusions were used during treatment.
The findings suggest the therapy may achieve clinical activity with significantly less administered radioactivity than current PRRT standards while potentially reducing treatment cycles from four to two, according to the company.
EBTATE is based on the company’s Evans Blue technology platform, which uses reversible albumin binding to extend circulation time and increase tumor retention. Molecular Targeting Technologies said preclinical studies have shown tumor retention levels as much as 26 times higher than conventional radiopharmaceutical approaches.
“The clinical experience in 81 patients validates both EBTATE and the broader Evans Blue platform,” Chairman and Chief Executive Officer Chris Pak said in a statement accompanying the data release.
Dr. Lisa Bodei, a nuclear medicine physician at Memorial Sloan Kettering Cancer Center, said the study demonstrated higher tumor uptake and longer tumor retention than conventional ¹⁷⁷Lu-DOTATATE while maintaining what she described as a favorable safety profile.
“The ability to deliver higher radiation doses to tumors with significantly lower administered radioactivity highlights the potential of this albumin-binding approach to improve the therapeutic index of PRRT,” Bodei said.
The company is continuing clinical development of EBTATE as it evaluates the therapy’s potential role in treating neuroendocrine tumors and other solid cancers.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.